Billion To One Skyrockets 15% — The "Google of Diagnostics" or a Post-IPO Bubble?
Billion To One's stock price increased by 15%, reaching double its post-IPO value due to its proprietary 'Molecular Counting' technology, which is claimed to be 1,000 times more sensitive than standard PCR. The company also has substantial cash reserves.